Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06262516 · ClinicalTrials.gov registry record · NA

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

A NA study of Urothelial Carcinoma, sponsored by Case Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
94
Enrollment target
4
Study locations

NCT06262516: Recruiting NA study of Urothelial Carcinoma, sponsored by Case Comprehensive Cancer Center.

NCT06262516 is a NA study of Urothelial Carcinoma that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 94 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (61% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06262516, a NA study of Urothelial Carcinoma, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
94 participants
Enrollment target
4
Study locations

Study Summary

The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are: * To determine oncologic outcomes, specifically 2-year recurrence-free survival * To determine other oncologic outcomes including treatment-free, cancer-specific and overall survival * To determine time to recurrence and recurrence patterns * To determine use of adjuvant therapies * To determine perioperative complications Participants will undergo nephroureterectomy with or without lymph node dissection. Researchers will compare these two groups to determine the oncologic efficacy of performing lymph node dissection.

Primary Outcome

Kaplan-Meier will compare recurrence-free survival time between participants who received LND vs participants who did not receive LND.

Conditions Studied

Interventions

  • PROCEDURE Nephroureterectomy
  • PROCEDURE Lymph Node Dissection

Study Locations (4)

Ohio

  • University Hospitals Cleveland Medical Center, Urology Institute, Case Comprehensive Cancer Center - Cleveland
  • Cleveland Clinic Glickman Urological and Kidney Institute - Cleveland

Florida

  • University of Florida Health Science Center - Gainesville

Illinois

  • Southern Illinois University - Springfield

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2024-05-17
Est. Completion 2029-01-01
Phase NA
Case Comprehensive Cancer Center

407 total trials

What NCT06262516 shows while recruiting

NCT06262516 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nephroureterectomy is the first listed.

NCT06262516 reports a single indexed study location in Ohio, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06262516 about?

NCT06262516 is a clinical study titled "Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma". The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are: * To determine oncologic outcomes, specifically 2-year recurr...

What is the current status of trial NCT06262516?

This trial is currently recruiting. It is a NA study. The enrollment target is 94 participants. The study started on 2024-05-17. Estimated completion is 2029-01-01.

What conditions does trial NCT06262516 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

What interventions are being tested in trial NCT06262516?

The interventions under investigation include: Nephroureterectomy (PROCEDURE), Lymph Node Dissection (PROCEDURE).

Who is sponsoring clinical trial NCT06262516?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06262516 being conducted?

This trial has 4 study locations across Florida, Illinois, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06262516's enrollment target sits among peer trials

94 39th of 85 higher than 47 of 85 other Urothelial Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03747146 · 94 participants · NA

    Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service

  • NCT04061421 · 94 participants · Phase 1

    Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

  • NCT04205968 · 94 participants · Phase 2

    Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

  • NCT04464759 · 94 participants · Phase 1

    A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06262516, the US trial registry maintained by the National Library of Medicine. NCT06262516 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.